Portfolio Category: Diagnostics

Autism is a life-long disability that as of today neither have a biological- based clinical diagnostics not an effective pharmacological treatment. Point6 Bio is a computational biology company focused on capturing multi-omics molecular insights from the proteome including from subject’s gut microbiome, to identify biomarker signatures, which will eventually affect treatment decision and new drug targets identification in Autism.

A company developing a liposome-based vaccine to treat different illness indications including, but not limited to, viral infections such as COVID-19

Nucleic acid-cationic polymer compositions of matter. May be used for treatment of cancer of the liver and pancreas as well as over thirty other types of cancers.

MyOR prevents a range of health issues using innovative, holistic solutions that combine predictive, noninvasive, monitoring technologies and customized products to help the body help itself. Our monitoring technologies leverage skin-sensing techniques and data science tools to gain new insight into systemic health and reveal the inner workings of your body. With these technologies in hand, MyOR customizes care solutions to prevent health conditions from developing.

LipoMedix is a development-stage privately held company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. The Company was established in order to advance the pharmaceutical and clinical development of a patented new chemical entity prodrug of mitomycin-C and its efficient delivery in liposomes to cancer-affected target organs. This formulation known as Promitil  – Pegylated Liposomal Mitomycin-C Prodrug (PL-MLP) – overcomes the problems associated with mitomycin-C toxicity and turn it into a state-of-the-art anti-cancer drug that will potentially become the therapy of choice in a variety of cancers, especially those derived from the gastrointestinal tract (stomach, pancreas, colorectal). The inventor and scientific founder, of LipoMedix is Prof. Alberto Gabizon of the Hebrew University – Shaare Zedek Medical Center who is also the co-inventor and co-developer of Doxil, (the first FDA-approved nano-drug in cancer therapy). As co-developer of Doxil® Prof. Gabizon is one of the few scientists intimately familiar with the successful development & commercialization process of liposomal drugs.

Cavos Biotech is an emerging genomic and data science company focusing on the development of novel drugs based on naturally occurring resistance mechanisms for various diseases. We are developing a multi-level genomic algorithm to uncover the genetic base of extraordinary cancer resistance found in specific, and across various animals. We harness the genomic and data revolution and use high resolution identification methods to uncover existing anti-cancer mechanisms, and novel drug targets, and to revolutionize the way by which drug targets are discovered and identified.

Viral diseases represent a serious health threat, exemplified by the recent COVID-19 pandemic. Moreover, viral diseases, such as Dengue, West Nile, and Zika fevers exact a particularly significant toll in the developing world. Relying on the results of two decades of research, ViroBlock plans to target and exploit a particular vulnerability in the viruses that cause these diseases: ion channels. Channels are critical components of the pathogen that enable it to regulate its salinity and acidity. Consequently, inhibiting such channels is a promising and validated route to curb viral infectivity. In particular, ViroBlock developed rapid screening approaches that can identify inhibitors from thousands of chemicals in a matter of weeks. Finally, focusing the screen on a library of approved drugs (repurposing) shortens the regulatory approval time dramatically, while lowering the risk.

Tissue Dynamics bionic microtissues are three dimensional human organoids embedded with electro optical sensors that provide critical insight into human-relevant mechanisms. These proprietary physiological models are powered by unprecedented AI & automation capabilities.